Physician profile
John A Magaldi
NPI 1740260058
$156,678.69
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $33K · 2021: $18K · 2022: $10K · 2023: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,734 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,733.75 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81,819.45 | 2019-2022 | |
| Pfizer INC. | $23,256.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22,427.25 | 2019-2020 | |
| Celgene Corporation | $16,272.00 | 2019 | |
| Amgen INC. | $12,778.75 | 2020-2023 | Tavneos, Otezla |
| Janssen Biotech, INC. | $93.58 | 2019-2023 | Tremfya |
| Ucb, INC. | $31.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Magaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.